2013 R&D Day in Lainate: Cosmo updates investors and analysts on progress and new developments in its R&D pipeline Freitag, 25. Januar 2013 - 06:57
2013 R&D Day in Lainate: Cosmo updates investors and analysts on progress and new developments in its R&D pipeline
Approval of Uceris™
Clinical development plan for colon cancer diagnostic
Progress report on topical acne and alopecia product
See http://www.cosmopharma.com/ir/presentations.aspx for more information
LAINATE – January 25, 2013. Cosmo Pharmaceuticals S.p.A. (SIX: COPN) will present to its shareholders, analysts and the financial press a comprehensive update on its clinical pipeline and its commercial implications at its R&D day to be held today at its headquarters in Lainate starting at 11:00 CET.
Highlights will include:
- Uceris™ was approved by the FDA on January 14 and the MEBs decision on Cortiment is expected shortly. CEO Mauro Ajani will elaborate on the next steps in the market introduction of Uceris™ by Santarus in the USA and CSO Dr. Luigi Moro will inform about the appeal process of Cortiment in the Netherlands.
- Presentation of phase II clinical study results and phase III clinical trial design of the colon cancer diagnostic Methylene Blue MMX. CSO Dr. Luigi Moro and Prof Dr. Alessandro Repici of Istituto Humanitas in Milano will present the data from the phase II clinical trial of colon cancer diagnosis with the Methylene Blue MMX® tablet and report on the clinical trial design process for the phase III. CEO Mauro Ajani will explain the business case and describe the time line to market.
- CB-03-01 for acne is in advanced phase II clinical trials in the USA. CSO Dr. Luigi Moro will inform about the clinical end points and the trial progress as well as the development of the alopecia formulation.
Mauro Ajani, CEO of Cosmo Pharmaceuticals, said, “The approval of Uceris™ is a watershed for Cosmo. It will vastly increase our revenue potential and it confirms the MMX technology’s versatility in colon applications. We have three additional products in development, two of them in a late stage and we look forwards towards updating the investor community and getting them to share our enthusiasm.”
The R&D day is expected to end around 16:00 CET.
Presentation online available on http://www.cosmopharma.com/ir/presentations.aspx
About Cosmo Pharmaceuticals
Cosmo is a speciality pharmaceutical company that aims to become a global leader in the field of optimized therapies for selected Gastrointestinal and topically treated Skin Disorders. The company’s proprietary clinical development pipeline specifically addresses innovative treatments for IBD, such as Ulcerative Colitis and Crohn’s Disease, and Colon Infections. In addition, the Company is developing a diagnostic for the detection of colon cancer and a new chemical entity for the topical skin treatment. Cosmo’s MMX® products that have reached the market are Lialda®/Mezavant®/Mesavancol®, a treatment for IBD that is licensed globally to Giuliani and Shire Limited and Uceris™, the first glucocorticosteroid indicated for the induction of remission in active, mild to moderate ulcerative colitis, licensed in US to Santarus, Inc. Cosmo’s proprietary MMX® technology is at the core of the Company’s product pipeline and was developed from its expertise in formulating and manufacturing gastrointestinal drugs for international clients at its GMP (Good Manufacturing Practice) facilities in Lainate, Italy. The technology is designed to deliver active ingredients in a targeted manner in the colon. For further information on Cosmo, please visit the Company’s website: www.cosmopharma.com
COSMO CONTACT:
Dr. Chris Tanner, CFO & Head of Investor Relations
Tel: +39 02 9333 7453
Fax: +39 02 9333 7663
Cautionary Statement Regarding Forward Looking Statements
This report and other material being released by Cosmo herewith contains statements that constitute “forward looking statements” including but not limited to managements outlook for Cosmo’s pipeline development and financial performance and statements relating to the anticipated effect of transactions and strategic initiatives on Cosmo’s business and future development. While these forward looking statements represent Cosmo’s judgments and expectations concerning the matters therein described, a number of risks, uncertainties and other important factors could cause actual developments and results to differ from Cosmo’s expectations.